Home / Resources / Sol-Gel Builds Awareness of Rare Skin Condition, Generates Leads

Sol-Gel Builds Awareness of Rare Skin Condition, Generates Leads

Case Study

Patient Engagement & Recruitment

OCT 23, 2025

A person types on a laptop and tablet, surrounded by email icons.

The Challenge

Sol-Gel Technologies specializes in innovative approaches to develop advanced treatments for patients with severe skin conditions. The company sought to enroll approximately 140 patients living with Gorlin syndrome, an extremely rare condition that affects an estimated 1 in 31,000 people. Because the enrollment was falling behind established timelines, Sol-Gel was forced to extend its screening dates.

Gorlin syndrome causes debilitating symptoms, including cancerous growths, facial abnormalities, and potentially life-threatening complications, significantly impacting quality of life. Patients can develop up to thousands of basal cell carcinoma (BCC) lesions on their skin, with invasive treatments being the only option, one that is not sustainable. Preventing the development of new BCC lesions is critical, and this study was for a topical gel representing a first-ever preventive therapy for these lesions.

The Goal

The campaign’s primary objective was to increase awareness of Gorlin syndrome and drive engagement with the Sol-Gel team.

World map illuminated by city lights and connected by a network of glowing lines and nodes.

The Solution

In an effort to boost enrollments rapidly, Citeline launched a 60-day HCP Awareness campaign for the study. Because time was of the essence, the campaign was launched in less than a month. Seven countries were included in the campaign: France, Germany, Italy, Netherlands, Spain, the UK, and the US.

Following the 60-day campaign, Citeline conducted a re-engagement campaign targeting interested HCPs from the initial campaigns. This subsequent campaign was conducted in Germany, the UK, and the US.